Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11875080 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Haq R, et al. (2002) Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem 277, 17359-66 11875080
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y368-p - EpoR (human)
Orthologous residues
EpoR (human): Y368‑p, EpoR (mouse): Y367‑p, EpoR (rat): Y367‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T183-p - JNK2 (human)
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y185-p - JNK2 (human)
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y701-p - STAT1 (human)
Orthologous residues
STAT1 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S727-p - STAT1 (human)
Orthologous residues
STAT1 (human): S727‑p, STAT1 (mouse): S727‑p, STAT1 (rat): S727‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase
PD98059 Epo inhibit treatment-induced increase
U0126 Epo inhibit treatment-induced increase
SB202190 Epo inhibit treatment-induced increase

Y705-p - STAT3 (human)
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S727-p - STAT3 (human)
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase
PD98059 Epo inhibit treatment-induced increase
U0126 Epo inhibit treatment-induced increase

Y694-p - STAT5A (human)
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S726-p - STAT5A (human)
Orthologous residues
STAT5A (human): S726‑p, STAT5A (mouse): S725‑p, STAT5A iso2 (mouse): , STAT5A (rat): S725‑p, STAT5A (fruit fly): , STAT5A (sheep): S726‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y699-p - STAT5B (human)
Orthologous residues
STAT5B (human): Y699‑p, STAT5B (mouse): Y699‑p, STAT5B (rat): Y699‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S731-p - STAT5B (human)
Orthologous residues
STAT5B (human): S731‑p, STAT5B (mouse): S730‑p, STAT5B (rat): S730‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.